Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLCVP for CSA-AKI Prevention
NCT05682716Completed
- Sponsor
- Nanjing First Hospital
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nitroglycerin in acute kidney injury (AKI) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Level of Serum creatinine at 90 days. Started Jul 2022; status: completed.
02
Drugs
nitroglycerin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05682716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682716.